Abstract

The central focus of laboratory core 9004 is to apply the in vitro Human Tumor Clonogenic Assay (HTCA) to aid in new anticancer drug development by the laboratory and clinical project investigators in this program project and for correlation with clinical trials. Drugs studied in HTCA include cytotoxic agents, chemosensitizers growth factors, growth factor antagonists and other biologics. HTCA is conducted primarily with fresh human tumors from biopsy specimens in order to gain information of potential in vivo relevance to new drug development, and to aid in drug selection for advancement to clinical trials and to identify desirable dosing schedules and plasma concentrations to be achieved in phase I clinical trials. Additionally, HTCA may aid in identification of tumor types and specific drug sensitive for recruitment into phase II trials of specific new agents tested. Other related studies are carried out with established human tumor cell lines which are also used in quality control for standardization of HTCA. Thus this laboratory core resource supports research activities of all projects investigators in this program project.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA017094-18A1
Application #
3749216
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721

  Publications

Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Jagadish, Bhumasamudram; Ozumerzifon, Tarik J; Roberts, Sue A et al. (2014) IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS. Synth Commun 44:
Barr, Paul M; Miller, Thomas P; Friedberg, Jonathan W et al. (2014) Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 124:1259-65
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87

Showing the most recent 10 out of 314 publications